These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19288753)

  • 21. The cycle of human herpes simplex virus infection: virus transport and immune control.
    Cunningham AL; Diefenbach RJ; Miranda-Saksena M; Bosnjak L; Kim M; Jones C; Douglas MW
    J Infect Dis; 2006 Sep; 194 Suppl 1():S11-8. PubMed ID: 16921466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neonatal herpes simplex virus infection.
    Malm G
    Semin Fetal Neonatal Med; 2009 Aug; 14(4):204-8. PubMed ID: 19230800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A tale of 2 alpha-herpesviruses: lessons for vaccinologists.
    Rouse BT; Kaistha SD
    Clin Infect Dis; 2006 Mar; 42(6):810-7. PubMed ID: 16477558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Herpes simplex: insights on pathogenesis and possible vaccines.
    Koelle DM; Corey L
    Annu Rev Med; 2008; 59():381-95. PubMed ID: 18186706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Herpes simplex virus vaccines: perspectives].
    Deback C; Huraux JM
    Rev Med Interne; 2007 Jan; 28(1):16-21. PubMed ID: 17095125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of herpes simplex virus infection and pathogenesis suggest a strategy for vaccine development.
    Xu X; Zhang Y; Li Q
    Rev Med Virol; 2019 Jul; 29(4):e2054. PubMed ID: 31197909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical management of herpes simplex virus infections: past, present, and future.
    Whitley R; Baines J
    F1000Res; 2018; 7():. PubMed ID: 30443341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccines for neonatal viral infections: vaccines to prevent neonatal herpes simplex virus infection.
    Jones CA
    Expert Rev Vaccines; 2004 Aug; 3(4):363-4. PubMed ID: 15270635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ocular HSV-1 latency, reactivation and recurrent disease.
    Toma HS; Murina AT; Areaux RG; Neumann DM; Bhattacharjee PS; Foster TP; Kaufman HE; Hill JM
    Semin Ophthalmol; 2008; 23(4):249-73. PubMed ID: 18584563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The potential impact of a prophylactic herpes simplex vaccine.
    Rupp R; Bernstein DI
    Expert Opin Emerg Drugs; 2008 Mar; 13(1):41-52. PubMed ID: 18321147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progress toward an elusive goal: current status of cytomegalovirus vaccines.
    Schleiss MR; Heineman TC
    Expert Rev Vaccines; 2005 Jun; 4(3):381-406. PubMed ID: 16026251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospects and perspectives for development of a vaccine against herpes simplex virus infections.
    McAllister SC; Schleiss MR
    Expert Rev Vaccines; 2014 Nov; 13(11):1349-60. PubMed ID: 25077372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Herpes simplex virus type 2: epidemiology and management options in developing countries.
    Paz-Bailey G; Ramaswamy M; Hawkes SJ; Geretti AM
    Postgrad Med J; 2008 Jun; 84(992):299-306. PubMed ID: 18644920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Situational antiviral drug prophylaxis for HSV type 1 recurrences.
    Hull C; Spruance S
    Herpes; 2007 Sep; 14(2):37-40. PubMed ID: 17939901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Echinacea purpurea polysaccharide reduces the latency rate in herpes simplex virus type-1 infections.
    Ghaemi A; Soleimanjahi H; Gill P; Arefian E; Soudi S; Hassan Z
    Intervirology; 2009; 52(1):29-34. PubMed ID: 19372701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chromatin control of herpes simplex virus lytic and latent infection.
    Knipe DM; Cliffe A
    Nat Rev Microbiol; 2008 Mar; 6(3):211-21. PubMed ID: 18264117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current vaccine approaches and emerging strategies against herpes simplex virus (HSV).
    Wijesinghe VN; Farouk IA; Zabidi NZ; Puniyamurti A; Choo WS; Lal SK
    Expert Rev Vaccines; 2021 Sep; 20(9):1077-1096. PubMed ID: 34296960
    [No Abstract]   [Full Text] [Related]  

  • 38. Introduction: objectives of herpes simplex virus vaccines seen from a historical perspective.
    Roizman B
    Rev Infect Dis; 1991; 13 Suppl 11():S892-4. PubMed ID: 1664123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.
    Stanfield B; Kousoulas KG
    Curr Clin Microbiol Rep; 2015 Sep; 2(3):125-136. PubMed ID: 27114893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurological complications of herpes simplex virus type 2 infection.
    Berger JR; Houff S
    Arch Neurol; 2008 May; 65(5):596-600. PubMed ID: 18474734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.